Human IL-23 antigen binding proteins

• US 9,487,580 B2
• Filed: 03/28/2014
• Issued: 11/08/2016
• Est. Priority Date: 10/26/2009
• Status: Active Grant

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: O'neill, Jason C., Towne, Jennifer E., Cheng, Janet D., Zhang, Yu, Sun, Yu, Cerne, Heather, Piper, Derek E., Ketchem, Randal R.
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US14/228,556
• Publication Number:
  US 20140212428A1
• Time in Patent Office: 956 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 47/6845 the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/626 Diabody or triabody
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

Claims

1. An isolated antigen binding protein that binds IL-23, comprising:

a CDRH1 of SEQ ID NO;

109;

a CDRH2 of SEQ ID NO;

116;

a CDRH3 of SEQ ID NO;

111;

a CDRL1 of SEQ ID NO;

80;

a CDRL2 of SEQ ID NO;

81; and

a CDRL3 of SEQ ID NO;

76.

4. An isolated antigen binding protein of claim 1, 2, or 3 wherein said antigen binding protein has at least one property selected from the group consisting of:

a) reducing human IL-23 activity;

b) reducing production of a proinflammatory cytokine;

c) binding to human IL-23 with a K_D of less than or equal to 5×

10<sup>−

8</sup> M;

d) having a K_off rate of less than or equal to 5×

10<sup>−

6</sup> 1/s; and

e) having an IC₅₀ of less than or equal to 400 pM.

5. A pharmaceutical composition comprising at least one antigen binding protein of claim 1, 2, or 3 and pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising at least one antigen binding protein of claim 4 and pharmaceutically acceptable excipient.

2. An isolated antigen binding protein that binds IL-23 comprising:

a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 100-109 of SEQ ID NO;

46 or 153; and

a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO;

15.

3. An isolated antigen binding protein that binds IL-23, comprising

a heavy chain variable region of SEQ ID NO:

46 and 153, and

a light chain variable region of SEQ ID NO;

15.